392 related articles for article (PubMed ID: 27863780)
1. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
2. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
[TBL] [Abstract][Full Text] [Related]
3. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
4. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
Kıvrak Salim D; Bayram S; Gömceli İ; Çekin AH; Karaca M; Koçer M; Yıldız M
Turk J Gastroenterol; 2019 Oct; 30(10):910-916. PubMed ID: 31625933
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Sadowski SM; Millo C; Neychev V; Aufforth R; Keutgen X; Glanville J; Alimchandani M; Nilubol N; Herscovitch P; Quezado M; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S676-82. PubMed ID: 26350374
[TBL] [Abstract][Full Text] [Related]
6. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
[TBL] [Abstract][Full Text] [Related]
7. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
8. Cocoon formation in patients with midgut neuroendocrine tumors: a rare and unrecognized final pathway.
Wang YZ; King H; Diebold A
Pancreas; 2013 Aug; 42(6):944-8. PubMed ID: 23587852
[TBL] [Abstract][Full Text] [Related]
9. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
[TBL] [Abstract][Full Text] [Related]
11. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
12. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
13. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
Aoki T; Kokudo N
Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
[No Abstract] [Full Text] [Related]
14. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
[TBL] [Abstract][Full Text] [Related]
15. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery.
Canellas R; Lo G; Bhowmik S; Ferrone C; Sahani D
J Magn Reson Imaging; 2018 Feb; 47(2):425-432. PubMed ID: 28480609
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms.
Attili F; Capurso G; Vanella G; Fuccio L; Delle Fave G; Costamagna G; Larghi A
Dig Liver Dis; 2014 Jan; 46(1):9-17. PubMed ID: 23731843
[TBL] [Abstract][Full Text] [Related]
19. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
20. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]